Statements (27)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
combination drug |
| gptkbp:activeIngredient |
gptkb:dapagliflozin
gptkb:saxagliptin |
| gptkbp:approvalYear |
2017
|
| gptkbp:approvedBy |
gptkb:European_Medicines_Agency
gptkb:U.S._Food_and_Drug_Administration |
| gptkbp:ATCCode |
A10BD15
|
| gptkbp:contraindication |
gptkb:type_1_diabetes_mellitus
gptkb:diabetic_ketoacidosis |
| gptkbp:form |
gptkb:tablet
|
| https://www.w3.org/2000/01/rdf-schema#label |
Qtern
|
| gptkbp:indication |
gptkb:type_2_diabetes_mellitus
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:marketingAuthorizationHolder |
gptkb:AstraZeneca
|
| gptkbp:mechanismOfAction |
SGLT2 inhibitor
DPP-4 inhibitor |
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:prescriptionStatus |
Rx only
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
gptkb:hypoglycemia
headache urinary tract infection upper respiratory tract infection nasopharyngitis |
| gptkbp:bfsParent |
gptkb:AstraZeneca_US
|
| gptkbp:bfsLayer |
6
|